Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology

Building a Future: Long-Term Monitoring and Family Health

At a Glance

Hereditary cardiac conduction disease requires lifelong, personalized monitoring even when you feel well or have a pacemaker. ECGs, rhythm recording, imaging, genetic testing, and screening of first-degree relatives can identify changes early and guide treatment.

Receiving a diagnosis of Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease is the start of a lifelong journey of monitoring. Because this condition is progressive and built into your DNA, “management” is not just about a single surgery or pill; it is about staying one step ahead of the electrical changes in your heart [1][2].

This page covers how you and your family can navigate the years ahead with confidence.

Your Long-Term Surveillance Schedule

Even if you feel healthy or have already received a pacemaker, regular check-ups are essential. The goal is to detect new “fast” rhythms (like AFib) or further “slow” signals before they cause symptoms [3][2].

  • ECG and Holter Monitoring: You will likely need a 12-lead ECG at least once a year to track your “intervals” (the timing of your heart’s electricity) [4]. Periodic Holter monitoring (a wearable recorder for 24–48 hours) is often used to catch “silent” rhythms that an ECG might miss, such as brief episodes of atrial fibrillation [5][6].
  • Structural Imaging: Depending on your gene, you may need an Echocardiogram or Cardiac MRI every 1 to 3 years. This is especially critical for those with LMNA or PRKAG2 mutations, where the heart muscle can thicken or weaken over time [7][8].
  • LMNA Risks: For those with the LMNA gene, in some specific cohorts, studies have observed an annual event risk of about 9%, emphasizing why missing an annual check-up is not recommended [2].

Protecting Your Family: Cascade Testing

Because this condition is hereditary, your diagnosis is a “lead” for your relatives. Cascade genetic testing is the standard of care—it involves testing your first-degree relatives (parents, siblings, and children) for the specific pathogenic variant found in you [9][10]. (Note that a Variant of Uncertain Significance should not be used for predictive testing).

  • Who should be tested?: Any first-degree relative should be offered genetic counseling and testing [9].
  • What if they feel fine?: Many people carry the gene but have a “normal” heart for many years. This is called incomplete penetrance [2]. However, because the disease is progressive, a relative with the gene needs regular clinical screening even if they feel perfect today [11].
  • The Benefit of Knowing: Identifying a gene carrier early allows for “active surveillance,” which can prevent sudden emergencies or strokes through early use of pacemakers or blood thinners [12][3].

Family Planning and the Next Generation

For many patients, the most difficult part of a genetic diagnosis is the concern for their children. It is important to know that you have options and a team of experts to help you navigate these choices.

  • Genetic Counseling: Before starting a family, meeting with a cardiovascular genetic counselor can help you understand the 50/50 chance of passing on the mutation [13].
  • Preconception Options: Some families choose Preimplantation Genetic Testing (PGT-M). This is a process used during IVF (In-Vitro Fertilization) to test embryos for the specific family mutation before they are implanted, substantially reducing the risk that the gene is passed to the next generation [14][15].
  • Multidisciplinary Care: Management during pregnancy should be handled by a “Heart Team” that includes cardiologists and high-risk OB-GYN specialists to ensure both parent and baby are monitored safely [14].

Living with the Condition

Living with a chronic, progressive condition requires a shift in mindset. It means viewing your pacemaker or ICD not as a sign of illness, but as a “security system” that allows you to live your life [16].

  • Device Awareness: If you have a device, you will have regular “remote monitoring” checks where your device sends data to your doctor via a bedside monitor [17]. Be sure to contact your clinic immediately if you experience signs of infection at the implant site, receive a device shock, or hear a device alert.
  • Daily Quality of Life: Most patients can return to normal activities, including exercise, though you should discuss your specific limits with your doctor, including any driving restrictions after fainting or an implant [18]. Managing stress and maintaining a heart-healthy lifestyle can help reduce the frequency of “fast” atrial rhythms [19].

By staying consistent with your monitoring and involving your family in the conversation, you transform a “rare disease” into a manageable part of your family’s health history.

Common questions in this guide

How often will I need ECGs and heart imaging for hereditary cardiac conduction disease?
Many people need a 12-lead ECG at least once a year and periodic Holter monitoring to look for rhythm changes that may not cause symptoms. Echocardiograms or cardiac MRI may be scheduled every one to three years, but the interval depends on the gene involved, test results, and your cardiologist’s plan.
Should my relatives have genetic testing if they feel healthy?
Yes. Parents, siblings, and children should be offered genetic counseling and testing for the known disease-causing variant because a person can carry it and have a normal heart for years. A relative who carries the variant still needs regular heart screening.
What does cascade genetic testing mean, and how is an uncertain result handled?
Cascade testing means testing parents, siblings, and children for the specific disease-causing variant identified in the family. A variant of uncertain significance should not be used to predict whether relatives will develop the condition, so a genetics professional should explain the result.
What are the chances of passing this condition to a child?
A parent who carries the familial disease-causing variant has a 50% chance of passing it to each child. Genetic counseling can explain this risk and options such as preimplantation genetic testing during IVF, which can test embryos for the family variant before implantation.
Do I still need monitoring after receiving a pacemaker or ICD?
Yes. A pacemaker or ICD can protect against certain dangerous rhythm problems, but it does not remove the need to monitor for atrial fibrillation, changes in heart structure, or progression of the inherited condition. Keep scheduled visits and remote device checks, and contact your clinic for a shock, device alert, or possible infection.

Get notified when new evidence is published on Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Current Topics of Progressive Cardiac Conduction Disease.

    Sumitomo N, Mori H, Kumamoto T, et al.

    Journal of arrhythmia 2026; (42(3)):e70383 doi:10.1002/joa3.70383.

    PMID: 42368294
  2. 2

    Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation.

    Hasselberg NE, Haland TF, Saberniak J, et al.

    European heart journal 2018; (39(10)):853-860 doi:10.1093/eurheartj/ehx596.

    PMID: 29095976
  3. 3

    Genetic testing in early-onset atrial fibrillation.

    Kany S, Jurgens SJ, Rämö JT, et al.

    European heart journal 2024; (45(34)):3111-3123 doi:10.1093/eurheartj/ehae298.

    PMID: 39028637
  4. 4

    Diagnosis, family screening, and treatment of inherited arrhythmogenic diseases in Europe: results of the European Heart Rhythm Association Survey.

    Conte G, Scherr D, Lenarczyk R, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(12)):1904-1910 doi:10.1093/europace/euaa223.

    PMID: 33367591
  5. 5

    Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Hershberger RE, Givertz MM, Ho CY, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2018; (20(9)):899-909 doi:10.1038/s41436-018-0039-z.

    PMID: 29904160
  6. 6

    Cardiac Abnormalities in First-Degree Relatives of Unexplained Cardiac Arrest Victims: A Report From the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry.

    Steinberg C, Padfield GJ, Champagne J, et al.

    Circulation. Arrhythmia and electrophysiology 2016; (9(9)).

    PMID: 27635072
  7. 7

    Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis.

    Lopez-Sainz A, Dominguez F, Lopes LR, et al.

    Journal of the American College of Cardiology 2020; (76(2)):186-197 doi:10.1016/j.jacc.2020.05.029.

    PMID: 32646569
  8. 8

    LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician.

    Rosario KF, Karra R, Amos K, et al.

    Journal of cardiac failure 2023; (29(12)):1657-1666 doi:10.1016/j.cardfail.2023.08.016.

    PMID: 37659618
  9. 9

    Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications.

    Girolami F, Frisso G, Benelli M, et al.

    Journal of cardiovascular medicine (Hagerstown, Md.) 2018; (19(1)):1-11 doi:10.2459/JCM.0000000000000589.

    PMID: 29176389
  10. 10

    Genetic testing for inherited arrhythmia syndromes and cardiomyopathies: results of the European Heart Rhythm Association survey.

    Zeljkovic I, Gauthey A, Manninger M, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2024; (26(9)) doi:10.1093/europace/euae216.

    PMID: 39148456
  11. 11

    Clinical care of family members of patients with dilated cardiomyopathy.

    Verdonschot JAJ, Kaski JP, Asselbergs FW, et al.

    European heart journal 2025; (46(43)):4569-4582 doi:10.1093/eurheartj/ehaf571.

    PMID: 40902100
  12. 12

    How does genetic susceptibility impact the effectiveness of AF ablation?

    Mililis P, Paraskevopoulou D, Saplaouras A, et al.

    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.08.005.

    PMID: 42648599
  13. 13

    Tips for Testing Adults With Suspected Genetic Kidney Disease.

    Savige J

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (83(6)):816-824 doi:10.1053/j.ajkd.2023.10.011.

    PMID: 38147894
  14. 14

    Bridging the Gap Between Genetic Cardiomyopathies and Pregnancy.

    Flores Rosario K, Hussien M, Grover P, et al.

    JACC. Advances 2026; (5(6 Pt 1)):102784 doi:10.1016/j.jacadv.2026.102784.

    PMID: 42132713
  15. 15

    Chinese experts' consensus guideline on preimplantation genetic testing of monogenic disorders.

    Yan L, Cao Y, Chen ZJ, et al.

    Human reproduction (Oxford, England) 2023; (38(38 Suppl 2)):ii3-ii13 doi:10.1093/humrep/dead112.

    PMID: 37982416
  16. 16

    Ventricular Fibrillation in PRKAG2 Cardiomyopathy: A Genetic Arrhythmia Substrate Beyond Wolff-Parkinson-White.

    Visch J, Hopman LHGA, Holtus D, et al.

    JACC. Case reports 2026; 110634 doi:10.1016/j.jaccas.2026.110634.

    PMID: 42853170
  17. 17

    External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study.

    Locati ET, Moya A, Oliveira M, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2016; (18(8)):1265-72 doi:10.1093/europace/euv311.

    PMID: 26519025
  18. 18

    Diagnosis and management of very rare primary arrhythmia syndromes in children and adults: a Clinical Consensus Statement of the European Heart Rhythm Association of the ESC and the Association of Cardiovascular Nursing & Allied Professions of the ESC, endorsed by the Association for European Paediatric and Congenital Cardiology.

    Sarquella-Brugada G, Mazzanti A, Baban A, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2026; (28(8)) doi:10.1093/europace/euag184.

    PMID: 42669047
  19. 19

    Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.

    Johner N, Gencer B

    European journal of clinical investigation 2026; (56(5)):e70224 doi:10.1111/eci.70224.

    PMID: 42148709

This page is for informational purposes only and does not constitute medical advice. Your cardiologist and genetic counselor should tailor monitoring, testing, and family-planning decisions to your family.

Guide contents Hereditary atrial tachyarrhythmia-infra-Hisian cardiac conduction disease
Research & Literature
05 Standard of Care